◀ Back to IL10

IL10 — MPO

Text-mined interactions from Literome

Barbara et al., Gut 2000 (Colitis) : IL-10 gene transfer prior to colitis improved colitis macroscopically and histologically, and significantly reduced colonic myeloperoxidase activity and leukotriene B4 concentrations
Han et al., J Ethnopharmacol 2013 : XXD promoted the recovery of colitis and inhibited the colonic inflammation damage in UC rats by reducing the level of MPO and the expression of TNF-a and NF-?Bp65, and increasing the production of IL-10 in colon tissues
Thompson et al., J Neurotrauma 2013 (Spinal Cord Injuries) : The best characterized effects of IL-10 are anti-inflammatory-it downregulates pro-inflammatory species interleukin-1ß (IL-1ß), interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor-a, interferon-?, matrix metalloproteinase-9, nitric oxide synthase, myeloperoxidase , and reactive oxygen species
Ribbons et al., Eur J Pharmacol 1997 (Colitis) : Interleukin-10 administered at 1, 10 and 100 micrograms/kg per day significantly reduced myeloperoxidase activity by 34, 57, and 28 %, respectively, compared to the placebo treated group, which was paralleled by an attenuation of colonic tumor necrosis factor alpha (TNF-alpha) content
Hayward et al., Eur J Pharmacol 1997 (Myocardial Reperfusion Injury) : Cardiac myeloperoxidase activity was also significantly ( P < 0.01 ) attenuated by interleukin-10 within the ischemic reperfused region compared to vehicle treated rats